Herein, we report a case of a 19-year-old man with multiple endocrine neoplasia type 2B (MEN2B) and medullary thyroid carcinoma (MTC) diagnosed when he was 12 years of age. The patient had previously undergone total thyroidectomy, cervical radiotherapy, and chemotherapy. He progressed with known bone, pulmonary, and lymph node metastases and was scanned with Ga-dotatate whole-body positron emission tomography/computed tomography (PET/CT) for metastatic disease monitoring. We found that the MTC bone metastases and soft tissue calcified metastases were better characterized on 18 F-NaF PET/CT than on 68 Ga-dotatate PET/CT. This case illustrates that the 18 F-NaF PET/CT could be helpful not only to the detection of bone metastases but also to the detection of calcified soft tissue metastases in patients with MTC.
Introduction
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy originating from the thyroid parafollicular C cells and, according to recent SEER (Surveillance, Epidemiology and End Results) data, accounts only for 1-2% of thyroid cancers in the USA [1] . The C cells secrete carcinoembryonic antigen (CEA) and calcitonin [2, 3] that are valuable tumor markers in patients with MTC [4] . Their serum concentrations are directly related to the C cell mass and simultaneous elevations of both in patients with MTC indicate disease progression [4] . In a study evaluating patients prior to thyroidectomy for MTC [5] , when the baseline serum calcitonin level was less than 500 pg/mL, no distant metastases were detected. In the postoperative follow-up, if the serum calcitonin level exceeds 150 pg/mL, patients should be evaluated by imaging procedures, including neck ultrasonography (US), chest computed tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or three-phase contrast-enhanced CT of the liver, bone scintigraphy, and MRI of the pelvis and axial skeleton [1] . Previous studies found that in patients with MTC, neck US is the most sensitive tool to detect cervical lymph node metastases [6] , CT is superior to any other technique to detect lung lesions [7] , and MRI is the most sensitive imaging modality for detection of hepatic and bone metastatic disease [8, 9] . However, bone scintigraphy and whole-body MRI (WB-MRI) were complementary for detection of bone metastases since WB-MRI may not always detect peripheral lesions located in the ribs, skull, and sternum [6, 10, 11] . Therefore, imaging MTC would consist in the combination of the aforementioned procedures [6] .
Regarding positron emission tomography/computed tomography (PET/CT) scan, only one study comparing 18 F-DOPA, 18 F-FDG, and somatostatin receptor PET/CT in recurrent MTC is available [12] . This study showed the superior diagnostic accuracy of 18 F-DOPA compared over other PET radiopharmaceuticals in this indication [12] . However, somatostatin receptor PET/CT may have an additional role as this method could be useful in pre-selecting metastatic MTC patients for therapy with cold or radiolabelled somatostatin analogues [13] . Nevertheless, the international guidelines do not recommend the use of any PET/CT tracers for restaging MTC with biochemical failure. The 2012 European Thyroid Association Guidelines for metastatic MTC recommend only the use of bone scintigraphy while the use of PET with 18 F-DOPA or 18 F-FDG is not advocated for its cost and low sensitivity, respectively [14] . In 2015, The Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma corroborated that neither 18 F-FDG-PET/CT nor 18 F-DOPA-PET/CT is recommended to detect the presence of distant metastases [1] . However, there are some objections to these guidelines and the European Association of Nuclear Medicine refuses to endorse some of the recommendations since they marginalize the utility of the nuclear medicine procedures in the management of the patients with MTC [15] . Gadotatate (b) PET coronal maximum intensity projection (MIP) images demonstrated uptake of both radiopharmaceuticals in multiple bone metastases (arrowheads). However, the metastases were better depicted on 18 F-fluoride PET/CT metastatic diseases. In the last years, there has been an increased clinical interest in the use of 18 F-NaF for bone disease assessment [16] . Reasons for this resurgence include the improved sensitivity of 18 F-NaF PET/CT compared with technetium-based conventional bone scans [17] , the quantitative potential of 18 F-NaF PET/CT [18] , and the periodic international shortages of Tc-99m needed for conventional bone scintigraphy [19] . Although the 18 F-NaF PET/CT scan has been evaluated in the assessment of metastatic bone disease in a variety of neoplastic disease, principally in prostate and breast cancer [20] , its use in MTC has been barely evaluated. In the herein reported case, we described the potential of the 18 F-NaF to detect not only bone metastatic disease but also calcified soft tissue disease in a patient with MTC.
Case Report
A 19-year-old man had multiple endocrine neoplasia type 2B (MEN2B) and MTC diagnosed when he was 12 years old. He was submitted to total thyroidectomy, cervical radiotherapy, and systemic chemotherapy with irinotecan and thalidomide. However, he progressed with known bone, pulmonary, and lymph node metastases and was started on vandetanib, a kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. He was scanned with 18 F-fluoride ( 18 F-NaF) and 68 Ga-dotatate whole-body positron emission tomography/computed tomography (PET/CT) for metastatic disease monitoring and also underwent a CT scan of the was possible to realize that most of the calcified soft tissue metastatic lesions presented 18 F-NaF uptake suggesting the high sensitivity of the method in the presented case (Figs. 2 and 3) . It was also noted that both PET/CT studies were equally capable to detect a cerebellum calcified metastasis (Fig. 4) .
Discussion
Conventional bone scintigraphy using 99m Tc-methylene diphosphonate ( 99m Tc-MDP) is one of the imaging techniques used to detect MTC metastatic disease in the skeleton. Its use in the management of MTC has been recommended by the guidelines of the American Thyroid Association [1, 14] . However, in the last years, PET/CT scanners have become increasingly available, and this has increased the interest in using 18 F-NaF PET/CT for skeletal imaging. As previously said, 18 F-NaF is a positron emission tracer used to evaluate benign and malignant bone diseases, mainly, bone metastatic diseases. Although the 18 F-NaF PET/CT scan has been evaluated in the assessment of metastatic disease in a variety of neoplastic disease [20] , its use in MTC has been barely described. Since Gadotatate uptake in bone metastatic lesions of MTC has been described in only one report [21] . This report described a single case of a patient for whom both methods were complementary in the detection of bone lesions and the comparison of the 18 F-NaF with other PET/CT tracers as well as with bone scintigraphy in the detection of skeletal metastases in patients with MTC has not been described. The lack of scientific studies on this topic should be due to the low prevalence of the disease [1] and the recent renewed interest of the use of the 18 F-NaF in the clinical practice [16] . Therefore, series of cases or case reports comparing 18 F-NaF with other imaging methods in the assessment of bone metastases in patients with MTC should be helpful to understand the role of this technology in clinical practice.
In addition, beyond the detection of bone metastases, 99m
Tc-MDP and 18 F-NaF can also detect calcified soft tissue metastases [22, 23] . Specifically in MTC cases, one report has described the capability of 99m Tc-MDP bone scintigraphy to detect calcified hepatic metastases [24] and there is also one report on the 18 F-NaF uptake in lymph nodal and hepatic MTC calcified metastatic lesions [25] . However, at the time being, there is no report comparing the 18 F-NaF detection of calcified soft tissue MTC metastases with other diagnostic imaging methods. This comparison would be interesting, since calcification is a frequent finding in soft tissue metastases of MTC [26] and the 18 F-NaF PET/CT could be useful in the detection of these metastases.
In this aspect, the herein reported case illustrates the potential of the 18 F-NaF to detect not only bone metastatic disease but also calcified soft tissue disease in a patient with MTC. In this case, the 18 F-NaF was superior to the 68 Ga-dotatate in the detection of metastatic sites in bone and calcified soft tissue metastases and depicted most of the soft tissue calcified lesions detected on the CT. The reason for this superiority of the 18 F-NaF could be a low expression of somatostatin receptors (SSTR) in some of the metastatic sites since this expression is variable [27] . Indeed, the sensitivity of 68 Ga-somatostatin analogue PET/CT in the detection of recurrence in patients with MTC has been reported to be limited and even in the same patient some metastatic sites present uptake of the radiopharmaceutical, while others do not [12] .
It is also interesting to note that the 18 F-NaF was capable to detect brain calcified metastases. This is particularly important since this is a region not routinely scanned in the algorithm recommended by the guidelines of the American Thyroid Association [1, 14] . Therefore, metastases in this region, although not common, could be missed using the current guidelines, and the use of 18 F-NaF PET/CT instead of conventional bone scintigraphy could be an opportunity to detect these metastases. In conclusion, this case suggests that at least in some situations, the 18 F-NaF PET/CT studies could be helpful in the detection of bone as well as calcified soft tissue metastases when in comparison with 68 Ga-dotatate PET/CT and conventional CT scan. Nonetheless, further analysis including a greater number of patients is required to confirm these findings.
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